Whenever you are excited about an idea or (the possibility of) an innovation, the first step is to talk to one of IXA’s business developers. Even if your idea is still premature and very much ‘under construction’. The sooner you let us know, the better – in particular when protection of intellectual property is at stake. We can inform you about the do’s and don’ts with respect to making your research data and results public.
We have specialized business developers for each research field. From engineering, maths and life sciences to the arts, humanities and social sciences*. They will support you in assessing the opportunities and potential pitfalls of your idea and advise you on the steps to be taken. Questions you can expect from our team are:
The best approach to further advance your idea depends largely on the idea itself and its stage of development. IXA supports in various steps:
In due time, we can assist in matchmaking with companies and investors with expertise, resources, and effective business networks. In addition, IXA can support you with legal and financial matters throughout the entire collaboration process.
* IXA has compiled valorisation guides especially tuned to researchers in social sciences and humanities (SSH) and life sciences (medical technology). Read more here.
We're here to assist you at every stage of the process
The ten winners of the prestigious Academic Startup Competition 2020 can use the title ‘Best Academic Startup of 2020’ for the coming year. The winning startups were chosen by an expert jury after a thrilling final in which all 20 finalists were asked to pitch. The ten winners were chosen on the basis of their value proposition, the […]News
On Friday November 20 State Secretary Mona Keijzer launched the national SME workshops digitization. The State Secretary for Economic Affairs and Climate talked to SME entrepreneurs and students. During the online event, Mona Keijzer launched the SME workshops by offering them to MKB Nederland. The majority of SME entrepreneurs are aware of the opportunities and […]News
LUMICKS, a spin-off of Vrije Universiteit Amsterdam, is pleased to announce a collaboration agreement with clinical-stage biotech company Leucid Bio, which seeks to utilize LUMICKS’ z-Movi® Cell Avidity Analyzer (z-Movi) to accelerate entry of immunotherapeutic candidates into clinical trials. The goal of the partnership is to evaluate the efficacy of Leucid Bio’s next-generation chimeric antigen […]News